The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Rapamycin Prevents Early Steps of the Development of Diabetic Nephropathy in Rats
Abstract
Background/Aims: Recent studies suggested the involvement of the Akt/mammalian target of rapamycin (mTOR) pathway in the pathogenesis of diabetic nephropathy. The effect of mTOR blockade by rapamycin in diabetic nephropathy was investigated, but in vivo study of rapamycin treatment in the course of early diabetes is still insufficient. This study was designed to determine the therapeutic effects of rapamycin on diabetic nephropathy at an early stage. Methods: Diabetes was induced in Sprague-Dawley rats with streptozotocin, and rapamycin (1 mg/kg) was administered by daily gavage for 4 weeks. Renal structural changes and some factors involved in the early pathogenesis of diabetic nephropathy were tested. The activation level of the Akt/mTOR pathway was also determined. Results: Rapamycin treatment reduced albuminuria, glomerular enlargement, glomerular basement membrane thickening, renal macrophage recruitment, and levels of renal mRNA expression of proliferating cell nuclear antigen, transforming growth factor-β 1, vascular endothelial growth factor, and monocyte chemoattractant protein-1 without change in blood glucose level and blood pressure in experimental diabetic rats. In addition, treatment with rapamycin also down-regulated the enhanced levels of renal p-Akt, phospho-p70S6 kinase, and phospho-ribosomal S6 protein in diabetic rats. Conclusions: Rapamycin treatment can prevent the early renal structural changes of diabetes in experimental rats, and thus halt the early steps of the development of diabetic nephropathy. mTOR blockade might be beneficial for the treatment of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mediators of Diabetic Renal Disease: The Case for TGF-β as the Major Mediator
Ziyadeh, F. N. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093460.24823.5b · Cited by 463
Cited by
Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications
Rovira-Llopis, S., Bañuls, C., Diaz-Morales, N., Hernandez-Mijares, A., Rocha, M., & Victor, V. M. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.013 · Cited by 657
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice
Inoki, K., Mori, H., Wang, J., Suzuki, T., Hong, S., Yoshida, S., Blattner, S. M., Ikenoue, T., Rüegg, M. A., Hall, M. N., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44771 · Cited by 538
Self-citationJin, J., Shi, Y., Gong, J., Zhao, L., Li, Y., He, Q., & Huang, H. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1177-1 · Cited by 365
Autophagy in diabetic nephropathy
Ding, Y., & Choi, M. E. (2015) · Journal of Endocrinology · doi:10.1530/joe-14-0437 · Cited by 306
Lenoir, O., Jasiek, M., Hénique, C., Guyonnet, L., Hartleben, B., Bork, T., Chipont, A., Flosseau, K., Bensaada, I., Schmitt, A., et al. (2015) · Autophagy · doi:10.1080/15548627.2015.1049799 · Cited by 296
Metadata
- Authors
- Yang, Y., Wang, J., Qin, L., Shou, Z., Zhao, J., Wang, H., Chen, Y., & Chen, J.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 27
- Issue
- 5
- Pages
- 495-502
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2061166531
- Cited by
- 174
- References
- 1
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin Prevents Early Steps of the Development of Diabetic Nephropathy in Rats. https://app.cochat.ai/papers/10.1159/000106782
- The paper
- Yang, Y., Wang, J., Qin, L., Shou, Z., Zhao, J., Wang, H., Chen, Y., & Chen, J. (2007). Rapamycin Prevents Early Steps of the Development of Diabetic Nephropathy in Rats. American Journal of Nephrology. https://doi.org/10.1159/000106782
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.